News

Q2 2025 Management View CEO Joseph E. Payne reported that the ARCT-032 program for Cystic Fibrosis (CF) has completed enrollment and dosing for the 5-milligram cohort and is advancing the 10-milligram ...
Allogene Therapeutics' Q2 2025 update highlights a streamlined ALPHA3 trial, promising ALLO-316 data, and financial discipline.
Net Sales Net sales in the 2026 first fiscal quarter were $17.6 million, an increase of $4.1 million, or 30.5%, compared to 2025 first fiscal quarter net sales of $13.5 million.
Revenue: $6.3 million for the first quarter of fiscal 2026 (period ended June 30, 2025), up 7% sequentially and 35% year over ...
Revenue for the first quarter of fiscal 2026 was $85.9 million, up 57.6% from $54.5 million in the same period in fiscal 2025. Gross margin under U.S. generally accepted accounting principles ...
"Our Compute Subsystems, CSS, are helping customers move faster and the demand has exceeded our expectations. Our first generation of CSS is now in market with five customers and is delivering double ...
Ralph Lauren Corporation (NYSE:RL), a global leader in the design, marketing, and distribution of luxury lifestyle products, today reported earnings per diluted share of $3.52, up 35% to prior year on ...
AstroNova Reports First-Quarter Fiscal 2026 Revenue Grew 14% Driven by Double Digit Growth in Both Aerospace and Product Identification Segments | Seeking Alpha ...